FDA Wants Generic Opioids to Be Abuse-Deterrent

Share this content:
FDA Wants Generic Opioids to Be Abuse-Deterrent
FDA Wants Generic Opioids to Be Abuse-Deterrent

FRIDAY, March 25, 2016 (HealthDay News) -- Continuing their push to combat the nation's epidemic of opioid abuse, U.S. officials on Thursday urged generic drug makers to take steps to redesign drugs such as hydrocodone and oxycodone to make them harder to abuse.

U.S. Food and Drug Administration officials said they were encouraging the generic drug industry to develop pain medicines with "abuse-deterrent properties." For instance, this would make it harder to crush a tablet to snort the contents or dissolve a capsule to inject its ingredients.

The FDA is also requiring makers of brand-name opioids with approved abuse-deterrent labeling to conduct long-term studies to see how effective the formulas are in reducing abuse in the real world. The agency said it realizes that these formulas aren't foolproof and more research is needed. But, given the lower cost of generic drugs, encouraging access to such drugs with abuse-deterrent properties is an important step toward reducing opioid abuse while helping to "ensure access to appropriate treatment for patients in pain," the FDA said.

The draft guidance includes recommendations about studies that should be done to prove that a generic drug is no less abuse-deterrent than a brand-name one. The FDA is asking for feedback from the generic drug industry during a 60-day comment period.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Salmonella Outbreak in 26 States Linked to Raw Turkey Products

<i>Salmonella</i> Outbreak in 26 States Linked to Raw ...

40 individuals have been hospitalized to date; no deaths have been reported

FDA Recalls Drugs Containing Active Ingredient Valsartan

FDA Recalls Drugs Containing Active Ingredient Valsartan

All lots of non-expired products that contain valsartan supplied by Zhejiang Huahai being recalled

Atopic Dermatitis Places Heavy Burden on Patients

Atopic Dermatitis Places Heavy Burden on Patients

Overall and mental health, life satisfaction all impacted, especially for moderate, severe disease

is free, fast, and customized just for you!




Already a member?

Sign In Now »